Metabolic uncoupling therapy

Abstract

A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

Description

CROSS-REFERENCE TO RELATED APPLICAIONS [0001] This Application is a divisional of U.S. patent application Ser. No. 10 / 462,958 filed on Jun. 17, 2003, which is a continuation-in-part under 37 CFR 1.53(b) of U.S. patent application Ser. No. 09 / 749,584 filed on Dec. 28, 2000, now U.S. Pat. No. 6,579,866, which issued Jun. 17, 2003.FIELD OF THE INVENTION [0002] This invention relates in general to novel concepts involving the metabolism of high-energy electrons in animals, and more particularly to their physiological effects in mammals. BACKGROUND OF THE INVENTION [0003] There is currently an epidemic of lifestyle related health disorders. These include, but are not limited to, high blood pressure, diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, insulin resistance, inflammation, vascular disease, heart disease, stroke, overweight, obesity, neuronal and / or cognitive dysfunction, dementia, attention and attention / hyperactivity disorders, mood disorders, muscular damage, musc...

AI Technical Summary

Benefits of technology

[0013] Various treatments in accordance with the present invention provide enhanced health benefits also by utilizing numerous synergistic mechanisms that together tend to reduce generation of ROS, reduce the PMF, and improve cellular redox status, based upon novel techniques described herein.

[0016] The proton-motive force (PMF) is generated by the pumping of protons across the mitochondrial membrane out of the mitochondrial matrix into the inter-membranous space outside the cell. It is coupled with passage of high-energy electrons down the ETC The potential energy generated by this separation of charge drives the production of ATP, which is coupled with proton passage back across the inner mitochondrial membrane into the matrix. This process collapses the PMF. The generation of reactive oxygen species is strongly dependent upon the magnitude of the PMF. Consumption of the PMF diminishes the concentration and half-life of semquinone moieties along the ETC. This reduces the rate of generation of reactive oxygen species, ROS. By collapsing the PMF, MPC serves to uncouple proton pumping from ATP-production. This lowers the generation of ROS. In the prior art, this insight suggested a key role for mitochondrial proton conductance (MPC). The uncoupling of proton pumping from the metabolism of ATP production formed a basis for regulating ROS in the prior art. In contrast, a primary function of MUT agents and MUT formulations in accordance with the present invention is to limit the accumulation of high-energy electrons potentially available to the electron transport chain.

[0017] A methodology of metabolic uncoupling therapy in accordance with the invention comprises: analyzing a specific physiologic process, including delineating the metabolic pathways related to reductive stress; identifying a plurality of MUT agents that modulate the metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

[0018] Further, a method preferably includes selection of MUT agents based on their interactions with each other to maximize synergy of the agents. In another aspect, a method includes combining specific amounts and ratios of a plurality of agents in a MUT formulation for administration in a prescribed manner for a prescribed period of time. Embodiments in accordance with the invention comprise compositions of chemical compounds, MUT agents, that are useful in metabolic uncoupling therapy. Selected chemical compounds, chemical species, dietary and pharmaceutical supplements and other nutritional agents (collectively “agents”) in specified amounts, prescribed ratios, and synergistic combinations are scientifically selected to act at one or multiple focal metabolic locations to maximize the desired beneficial results, while simultaneously minimizing undesired side effects.

[0021] MUT agents in accordance with the invention act in various specific combinations, compositions, amounts, and ratios to maximize beneficial effects. Further, MUT in accordance with the invention minimizes adverse side effects that might otherwise occur through inappropriate usage of various compounds and compositions not in accordance with the invention. Because of these beneficial effects, MUT may be utilized for the prevention of a multitude of conditions, in addition to its use as a therapeutic modality under conditions of disease and aging.

Problems solved by technology

There is currently an epidemic of lifestyle related health disorders.

Our “stone age” genes are a poor match for the demands placed upon them by our current lifestyles.

A perturbation in a metabolic pathway that produces changes exceeding the normal ranges developed through evolution forces may ultimately derail the delicate chemical balance that forms the basis for cellular homeostasis.

This only allowed generation of meager amounts of energy.

This benefit was accompanied by the problems of coping with the corrosive and reactive oxygen molecule.

Even though prevention rather than cure is a more logical way to decrease oxidative damage, no attention has been paid to processes that are critical in the production or generation of ROS.